Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of selected advanced or metastatic
             solid tumors.

          -  Presence of measurable disease per RECIST v1.1.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Baseline archival tumor specimen available or willingness to undergo a pretreatment
             tumor biopsy to obtain the specimen.

          -  Resolution of treatment-related toxicities.

          -  Adequate hepatic, renal, cardiac, and hematologic function.

          -  Additional cohort-specific criteria may apply.

        Exclusion Criteria:

          -  Subjects who participated in any other study in which receipt of an investigational
             study drug or device occurred within 28 days or 5 half-lives (whichever is longer)
             prior to first dose.

          -  Has received a prior monoclonal antibody within 4 weeks or 5 half-lives (whichever is
             shorter) before administration of study drug.

          -  Has had prior chemotherapy or targeted small molecule therapy within 2 weeks before
             administration of study treatment.

          -  Has received prior approved radiotherapy within 14 days of study therapy.

          -  Has had known additional malignancy that is progressing or requires active treatment,
             or history of other malignancy within 2 years of study entry.

          -  Has an active autoimmune disease that has required systemic treatment in past 2 years.

          -  Has an active infection requiring systemic therapy.

          -  Has known active CNS metastases and/or carcinomatous meningitis.

          -  Women who are pregnant or breastfeeding.